RÉSUMÉ
BACKGROUND: Biological therapies are effective for psoriasis, but patient responses vary, often requiring therapy switching or discontinuation. OBJECTIVES: To identify physicians' prescribing patterns of biological therapies at a referral tertiary center in Saudi Arabia and assess the probability of biologic persistence following treatment initiation. METHODS: We conducted a retrospective study of biologic-naïve adult psoriasis patients who initiated therapy from October 2013 to July 2022 in Dammam. Descriptive statistics and a Kaplan-Meier analysis evaluated treatment persistence at 6, 12, 24, and 36 months. RESULTS: A total of 151 patients received adalimumab (n = 89), etanercept (n = 17), risankizumab (n = 30), ustekinumab (n = 14), and ixekizumab (n = 1). At 6 months, all therapies demonstrated 100% persistence. At 12 months, persistence was highest for ustekinumab (100%) and lowest for etanercept (88.2%). At 24 months, ustekinumab maintained 100% persistence, followed by risankizumab (96.6%), adalimumab (94.3%), and etanercept (76.4%). At 36 months, risankizumab had the highest persistence (96.6%), followed by adalimumab (83.1%), ustekinumab (78%), and etanercept (70.6%). The most common reasons for discontinuation were lack of effectiveness and intolerability. CONCLUSION: This study shows changing psoriasis treatment patterns with new therapies. Risankizumab demonstrated high long-term persistence, while etanercept and ustekinumab showed declining persistence, suggesting evolving treatment considerations.
Sujet(s)
Adalimumab , Étanercept , Types de pratiques des médecins , Psoriasis , Ustékinumab , Humains , Psoriasis/traitement médicamenteux , Études rétrospectives , Arabie saoudite , Mâle , Femelle , Adulte , Adulte d'âge moyen , Types de pratiques des médecins/statistiques et données numériques , Ustékinumab/usage thérapeutique , Étanercept/usage thérapeutique , Adalimumab/usage thérapeutique , Anticorps monoclonaux humanisés/usage thérapeutique , Produits dermatologiques/usage thérapeutique , Produits biologiques/usage thérapeutique , Adhésion au traitement médicamenteux/statistiques et données numériques , Anticorps monoclonaux/usage thérapeutique , BiothérapieRÉSUMÉ
Many diseases originate from either the absence or defective expression of a given protein. For some of them, the lacking protein is secreted or can be taken up by cells when delivered exogenously. In such cases, therapies initially involved administering the physiological protein extracted from human tissues. Subsequently, genetic engineering enabled the production of proteins through cell fermentation after introducing the corresponding gene. For many other pathologies, the deficient protein cannot be delivered exogenously. Thus, an endogenous production of the therapeutic protein by the cells themselves is necessary. Messenger RNA (mRNA) technology, like its predecessor DNA, aims to supplement the genetic information needed to produce the therapeutic protein within the cells. However, unlike DNA-based therapies, mRNA transfer allows for transient expression of the protein of interest, which offers an advantage in numerous pathologies. Nonetheless, mastering the quantity, quality, and spatio-temporal regulation of protein production encoded by therapeutic mRNA remains a significant challenge for the development of this approach.
Title: « ReNAissance ¼1 des biothérapies par ARN. Abstract: Nombre de maladies ont pour origine une absence d'expression ou une expression défectueuse d'une protéine donnée. Pour certaines d'entre elles, la protéine faisant défaut est circulante et peut être captée par les cellules lorsqu'elle est délivrée de façon exogène. Dans ce cas, les thérapies ont d'abord consisté en l'administration de la protéine thérapeutique extraite de tissus humains. Par la suite, le génie génétique a permis la production des protéines par fermentation de cellules après y avoir introduit le gène correspondant. Pour beaucoup d'autres maladies, la protéine faisant défaut ne peut être délivrée de façon exogène. Une production endogène de la protéine thérapeutique, par les cellules elles-mêmes est donc nécessaire. La technologie de l'ARN messager (ARNm), comme celle la précédant de l'ADN, se propose de supplémenter, au cÅur des cellules, l'information génétique nécessaire pour produire elles-mêmes la protéine thérapeutique. Cependant, contrairement aux thérapies utilisant l'ADN, le transfert d'ARNm permet une expression transitoire de la protéine d'intérêt ce qui constitue un avantage dans nombre de maladies. La maîtrise de la quantité, de la qualité et de la régulation spatio-temporelle de la production d'une protéine codée par l'ARNm thérapeutique représente, néanmoins, un défi important pour le développement de cette approche.
Sujet(s)
ARN messager , Humains , ARN messager/génétique , Thérapie génétique/méthodes , Thérapie génétique/tendances , Animaux , Biothérapie/méthodes , Biothérapie/tendances , ARN/génétiqueRÉSUMÉ
BACKGROUND: This study's purposes were to evaluate the impact of biological therapies on outcomes in patients with severe asthma (SA) and chronic rhinosinusitis (CRS) and to compare these effects among those with NP (CRSwNP) versus those without NP (CRSsNP) in the "real-world" setting in Saudi Arabian patients. METHODS: From March to September 2022, a retrospective observational cohort study was undertaken at the severe asthma clinics of the Armed Forces Hospital-Southern Region (AFHSR) and King Khalid University Hospital, Abha, Saudi Arabia, to delineate the effects of dupilumab therapy. Outcomes were assessed, including clinical outcomes, FEV1, and laboratory findings before and one year after dupilumab. Post-therapy effects were compared between CRSwNP and CRSsNP. RESULTS: Fifty subjects were enrolled, with a mean age of 46.56. There were 27 (54%) females and 23(46%) males. Significant improvements in clinical parameters (frequency of asthma exacerbations and hospitalizations, the use of OCs, anosmia, SNOTT-22, and the ACT), FEV1, and laboratory ones (serum IgE and eosinophilic count) were observed 6 and 12 months after using dupilumab (p < 0.001), respectively. However, after 12 months of dupilumab therapy, there were no significant differences between those with and without NP with regards to clinical (anosmia, ACT, and OCs use), laboratory (eosinophilic count, serum IgE level) parameters, and FEV1%. CONCLUSIONS: Patients with CRS experienced significant improvements in clinical, FEV1, and laboratory outcomes after dupilumab therapy. However, these improvements were not maintained when comparing CRSwNP with CRSsNP. There were no significant differences between those with and without NP regarding ACT and OCs use or laboratory (eosinophilic count, serum IgE level) parameters. Further prospective multicenter studies are warranted.
Sujet(s)
Anticorps monoclonaux humanisés , Asthme , Polypes du nez , , Adulte , Femelle , Humains , Mâle , Adulte d'âge moyen , Anticorps monoclonaux humanisés/usage thérapeutique , Asthme/traitement médicamenteux , Biothérapie/méthodes , Maladie chronique , Immunoglobuline E/sang , Polypes du nez/traitement médicamenteux , Polypes du nez/complications , Études rétrospectives , /complications , /traitement médicamenteux , Arabie saoudite , Indice de gravité de la maladie , Résultat thérapeutiqueRÉSUMÉ
INTRODUCTION: The advent of biological therapies has already revolutionized treatment strategies and disease course of several rheumatologic conditions, and monoclonal antibodies (mAbs) targeting cytokines and interleukins represent a considerable portion of this family of drugs. In systemic lupus erythematosus (SLE) dysregulation of different cytokine and interleukin-related pathways have been linked to disease development and perpetration, offering palatable therapeutic targets addressable via such mAbs. AREAS COVERED: In this review, we provide an overview of the different biological therapies under development targeting cytokines and interleukins, with a focus on mAbs, while providing the rationale behind their choice as therapeutic targets and analyzing the scientific evidence linking them to SLE pathogenesis. EXPERT OPINION: An unprecedented number of clinical trials on biological drugs targeting different immunological pathways are ongoing in SLE. Their success might allow us to tackle present challenges of SLE management, including the overuse of glucocorticoids in daily clinical practice, as well as SLE heterogenicity in treatment response among different individuals, hopefully paving the way toward precision medicine.
Sujet(s)
Anticorps monoclonaux , Développement de médicament , Interleukines , Lupus érythémateux disséminé , Humains , Lupus érythémateux disséminé/traitement médicamenteux , Lupus érythémateux disséminé/immunologie , Anticorps monoclonaux/pharmacologie , Anticorps monoclonaux/administration et posologie , Interleukines/antagonistes et inhibiteurs , Interleukines/immunologie , Animaux , Thérapie moléculaire ciblée , Cytokines/métabolisme , Cytokines/antagonistes et inhibiteurs , Cytokines/immunologie , Médecine de précision , Glucocorticoïdes/pharmacologie , Glucocorticoïdes/administration et posologie , Biothérapie/méthodesRÉSUMÉ
INTRODUCTION: Biological therapies have become the standard treatment for ulcerative colitis (UC). However, clinical remission rates post-induction therapy remain modest at 40-50%, with many initial responders losing response over time. Current treatment strategies frequently rely on a 'trial and error' approach, leading to prolonged periods of ineffective and costly therapies for patients, accompanied by associated treatment complications. AREA COVERED: This review discusses current evidence on risk stratification tools for predicting therapeutic efficacy and minimizing adverse events in UC management. Recent studies have identified predictive factors for biologic therapy response. In the context of personalized medicine, the goal is to identify patients at high risk of progression and complications, as well as those likely to respond to specific therapies. Essential risk stratification tools include clinical decision-making aids, biomarkers, genomics, multi-omics factors, endoscopic, imaging, and histological assessments. EXPERT OPINION: Employing risk stratification tools to predict therapeutic response and prevent treatment-related complications is essential for precision medicine in the biological management of UC. These tools are necessary to select the most suitable treatment for each individual patient, thereby enhancing efficacy and safety.
Sujet(s)
Rectocolite hémorragique , Médecine de précision , Humains , Rectocolite hémorragique/traitement médicamenteux , Rectocolite hémorragique/thérapie , Rectocolite hémorragique/diagnostic , Biothérapie/méthodes , Appréciation des risques , Résultat thérapeutiqueRÉSUMÉ
INTRODUCTION: Advanced hepatocellular carcinoma (HCC) represents a significant global health burden, whose treatment has been recently revolutionized by the advent of biologic treatments. Despite that, innovative therapeutic regimens and approaches, especially immune-based, remain to be explored aiming at extending the therapeutic benefits to a wider population of patients. AREAS COVERED: This review comprehensively discusses the evolving landscape of biological treatment modalities for advanced HCC, including immune checkpoint inhibitors, antiangiogenic monoclonal antibodies, tumor-targeting monoclonal antibodies either naked or drug-conjugated, therapeutic vaccines, oncolytic viruses, adoptive cell therapies, and cytokine-based therapies. Key clinical trials and preclinical studies are examined, highlighting the actual or potential impact of these interventions in reshaping treatment paradigms for HCC. EXPERT OPINION: Tailored and rational combination strategies, leveraging the synergistic effects of different modalities, represent a promising approach to maximize treatment efficacy in advanced HCC, which should aim at conversion endpoints to increase the fraction of patients eligible for curative approaches. The identification of predictive biomarkers holds the key to optimizing patient selection and improving therapeutic outcomes.
Sujet(s)
Produits biologiques , Carcinome hépatocellulaire , Tumeurs du foie , Humains , Carcinome hépatocellulaire/thérapie , Carcinome hépatocellulaire/immunologie , Carcinome hépatocellulaire/anatomopathologie , Tumeurs du foie/thérapie , Tumeurs du foie/anatomopathologie , Tumeurs du foie/immunologie , Tumeurs du foie/traitement médicamenteux , Produits biologiques/usage thérapeutique , Animaux , Biothérapie/méthodes , Immunothérapie , Inhibiteurs de points de contrôle immunitaires/usage thérapeutiqueSujet(s)
Antiasthmatiques , Asthme , Induction de rémission , Humains , Asthme/traitement médicamenteux , Antiasthmatiques/usage thérapeutique , Indice de gravité de la maladie , Mâle , Femelle , Biothérapie/méthodes , Adulte d'âge moyen , Produits biologiques/usage thérapeutique , Adulte , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND/OBJECTIVES: Royal Darwin Hospital (RDH) is the sole public dermatology service in the Northern Territory (NT). Prescription of biologic therapies (BT) in the NT is uniquely challenging, with remote populations carrying a high tropical disease burden. The aim of this audit is to examine the demographics and outcomes of patients on BT for dermatologic conditions. METHODS: Retrospective case note review of patients receiving BT through the RDH Dermatology department between August 2021 and October 2023. Data analysed were demographics, location, dermatological diagnosis and serology status. RESULTS: In this audit, 115 patients were included. Age range of 13-91 years, mean of 51.1 years (±14.7), 52 (45.2%) patients were female and 8 (7.8%) identified as First Nations Australian. A large geographical area was serviced, with a primary address between 1 and 1496 km from RDH. Eighteen patients (15.7%) have discontinued BT completely. There was a statistically significant relationship between cessation of BT and increased distance of primary residence from RDH (p < 0.0007). Eighteen patients (15.7%) required management of infections identified in opportunistic infection screening. These infections were strongyloidiasis, tuberculosis, melioidosis and hepatitis B. CONCLUSIONS: There is significant anxiety surrounding BT and tropical infections, including in returning travellers in southern Australian states. There has been particular interest in strongyloidiasis infection, as dupilumab acts on the Th2 immunity mechanism critical to parasitic infection response. This audit exhibits the unique experience of dermatological care in a tropical setting, demonstrating how BT can be used safely and how, when identified, these tropical infections can be successfully managed.
Sujet(s)
Infections opportunistes , Humains , Femelle , Adulte d'âge moyen , Mâle , Adulte , Sujet âgé , Études rétrospectives , Territoire du Nord/épidémiologie , Adolescent , Jeune adulte , Sujet âgé de 80 ans ou plus , Infections opportunistes/épidémiologie , Maladies de la peau , Biothérapie/effets indésirablesRÉSUMÉ
INTRODUCTION: Approximately 20-30% of the patients with ulcerative colitis (UC) may present with isolated proctitis. Ulcerative proctitis (UP) is a challenging condition to manage due to its significant burden in terms of disabling symptoms. AREAS COVERED: PubMed was searched up to March 2024 to identify relevant studies on UP. A comprehensive summary and critical appraisal of the available data on UP are provided, highlighting emerging treatments and areas for future research. EXPERT OPINION: Patients with UP are often undertreated, and the disease burden is often underestimated in clinical practice. Treat-to-target management algorithms can be applied to UP, aiming for clinical remission in the short term, and endoscopic remission and maintenance of remission in the long term. During their disease, approximately one-third of UP patients require advanced therapies. Escalation to biologic therapy is required for refractory or steroid dependent UP. For optimal patient care and management of UP, it is necessary to include these patients in future randomized clinical trials.
Sujet(s)
Biothérapie , Rectocolite hémorragique , Rectite , Humains , Rectocolite hémorragique/complications , Rectocolite hémorragique/thérapie , Rectocolite hémorragique/traitement médicamenteux , Rectocolite hémorragique/diagnostic , Rectite/traitement médicamenteux , Rectite/thérapie , Biothérapie/méthodes , Induction de rémission , AlgorithmesRÉSUMÉ
Desarrollar guías actualizadas para el manejo farmacológico de la artritis reumatoide (AR). Se conformó un grupo de expertos que fueran representativos de las distintas regiones geográficas y los diferentes servicios médicos que atienden a la población mexicana con AR. Se desarrollaron preguntas basadas en Población, Intervención, Comparación y Desenlace [Outcome] (PICO) que fueron consideradas relevantes desde el punto de vista clínico; las preguntas encontraron su respuesta en los resultados de una revisión sistemática de la literatura (RSL) reciente y la validez de la evidencia fue evaluada mediante el sistema GRADE, considerado un estándar para estos fines. Posteriormente, el grupo de expertos desarrollaró un acuerdo en la dirección y fuerza de las recomendaciones mediante un proceso de votación en distintas etapas. Las guías actualizadas para el tratamiento de la AR categorizan en forma estratificada a las distintas opciones terapéuticas incluyendo las distintas familias de fármacos modificadores de la enfermedad (FARME): convencionales, biológicos e inhibidores de JAK), además de AINE, glucocorticoides y analgésicos. Establece por consenso el uso de todos ellos en distintas subpoblaciones de interés de pacientes con AR, y aborda, además, aspectos relacionados con la vacunación, la COVID-19, la cirugía, el embarazo y la lactancia entre otros. La presente actualización de las guías mexicanas para el tratamiento farmacológico de la AR brinda elementos de referencia en la toma de decisiones basados en la evidencia científica más reciente, y recomienda la participación del paciente para la toma de decisiones conjuntas en la búsqueda del mayor beneficio de nuestros pacientes; establece además, recomendaciones para el manejo de una diversidad de condiciones relevantes que afectan a nuestros pacientes.
Sujet(s)
Humains , Polyarthrite rhumatoïde/traitement médicamenteux , Biothérapie , Antirhumatismaux/usage thérapeutique , MexiqueRÉSUMÉ
N-glycosylation of the Fc part is a (critical) quality attribute of therapeutic antibodies and Fc-containing biotherapeutics, that impacts their stability, immunogenicity, pharmacokinetics, and effector functions. Current glycosylation analysis methods focus on the absolute amounts of glycans, neglecting the apparent glycan distribution over the entirety of proteins. The combination of the two Fc N-glycans, herein referred to as glyco-pair, therefore remains unknown, which is a major drawback for N-glycan impact assessment. This study presents a comprehensive workflow for the analysis and characterization of Fc N-glycan pairing in biotherapeutics, addressing the limitations of current glycosylation analysis methods. The applicability of the method across various biotherapeutic proteins including antibodies, bispecific antibody formats, and a Fc-Fusion protein is demonstrated, and the impact of method conditions on glycan pairing analysis is highlighted. Moreover, the influence of the molecular format, Fc backbone, production process, and cell line on glycan pairing pattern was investigated. The results underscore the significance of comprehensive glycan pairing analysis to accurately assess the impact of N-glycans on important product quality attributes of therapeutic antibodies and Fc-containing biotherapeutics.
Sujet(s)
Anticorps , Biothérapie , Polyosides , Polyosides/composition chimique , Polyosides/métabolisme , Anticorps/composition chimique , Anticorps/usage thérapeutique , Glycosylation , Biothérapie/méthodes , Flux de travaux , Glycosidases/métabolisme , Fucose/composition chimiqueSujet(s)
Antiasthmatiques , Asthme , Induction de rémission , Centres de soins tertiaires , Humains , Asthme/traitement médicamenteux , Enfant , Femelle , Mâle , Antiasthmatiques/usage thérapeutique , Antiasthmatiques/administration et posologie , Résultat thérapeutique , Adolescent , Indice de gravité de la maladie , Enfant d'âge préscolaire , Biothérapie , Études rétrospectivesRÉSUMÉ
Malignant tumors pose a grave threat to the quality of human life. The prevalence of malignant tumors in China is steadily rising. Presently, clinical interventions encompass surgery, radiotherapy, and pharmaceutical therapy in isolation or combination. Nonetheless, these modalities fail to completely eradicate malignant tumor cells, frequently leading to metastasis and recurrence. Conversely, tumor biotherapy has emerged as an encouraging fourth approach in preventing and managing malignant tumors owing to its safety, efficacy, and minimal adverse effects. Currently, a range of tumor biotherapy techniques are employed, including gene therapy, tumor vaccines, monoclonal antibody therapy, cancer stem cell therapy, cytokine therapy, and adoptive cellular immunotherapy. This study aims to comprehensively review the latest developments in biological treatments for malignant tumors.
Sujet(s)
Biothérapie , Tumeurs , Humains , Tumeurs/thérapie , Biothérapie/méthodes , Vaccins anticancéreux/usage thérapeutique , Thérapie génétique/méthodes , Immunothérapie/méthodes , ChineRÉSUMÉ
Severe asthma is a complex and heterogeneous chronic airway inflammatory disease. Current treatment strategies are increasingly focused on disease classification, facilitating the transition towards personalized medicine by integrating biomarkers and monoclonal antibodies for tailored therapeutic approaches. Several approved biological agents, including anti-immunoglobulin E (IgE), anti-interleukin (IL)-4, anti-IL-5, and anti-thymic stromal lymphopoietin (TSLP) monoclonal antibodies, have demonstrated significant efficacy in reducing asthma exacerbations, eosinophil counts, improving lung function, minimizing oral corticosteroid usage, and enhancing patients' quality of life. The utilization of these biological agents has brought about profound transformations in the management of severe asthma. This article provides a comprehensive review on biomarkers and biological agents for severe asthma while emphasizing the increasing importance of further research into its pathogenesis and novel treatment modalities.
Sujet(s)
Asthme , Médecine de précision , Humains , Asthme/traitement médicamenteux , Asthme/immunologie , Antiasthmatiques/usage thérapeutique , Marqueurs biologiques , Animaux , Thérapie moléculaire ciblée , Anticorps monoclonaux/usage thérapeutique , Cytokines/métabolisme , Biothérapie/méthodesRÉSUMÉ
Eosinophilic otitis media (EoOM) is a variant of exudative otitis media characterized by a persistent persistent course, the presence of a very viscous effusion in the tympanic cavity, comorbidally associated with chronic polypous rhinosinusitis and bronchial asthma. The disease is characterized by a persistent progressive course, which can lead to a gradual decrease in hearing up to complete deafness. Conservative treatment methods for EoOM include local and systemic administration of glucocorticosteroids. Encouraging data on the effectiveness of biological therapy have appeared in recent publications. The above clinical observation examines the course of EoOM in a patient who received biological therapy with dupilamab.
Sujet(s)
Otite moyenne sécrétoire , Rhinite , Sinusite , Humains , Sinusite/complications , Sinusite/thérapie , Sinusite/diagnostic , Rhinite/thérapie , Rhinite/complications , Rhinite/traitement médicamenteux , Maladie chronique , Résultat thérapeutique , Otite moyenne sécrétoire/étiologie , Otite moyenne sécrétoire/diagnostic , Otite moyenne sécrétoire/thérapie , Éosinophilie/complications , Mâle , Femelle , Biothérapie/méthodes ,RÉSUMÉ
BACKGROUND: The rise of biologic agents has been a major breakthrough in treating immune-mediated inflammatory diseases (IMIDs). However, their high cost underscores the need for strategies to optimize treatment efficiency. Biosimilars offer cost-effective alternatives to biologics. This study aimed to assess biosimilar drug availability's impact on biologic therapy access for IMIDs. RESEARCH DESIGN AND METHODS: A retrospective observational study in 15 Spanish hospitals analyzed IMID patients (arthropathies, inflammatory bowel disease and psoriasis) initiating biologic therapy with originator or biosimilar drugs (infliximab, etanercept, adalimumab). Time to availability and initiation of biologic therapy were assessed. RESULTS: 267 patients were included, with 58.4% starting on biosimilars. The mean time to availability of the biologic drugs in the hospitals was 15.9 ± 6.7 months, (20.0 ± 12.4 for originator and 11.8 ± 5.2 for biosimilars). Mean time to biologic treatment was 7.7 ± 9.0 years (8.6 ± 8.9 for originators and 7.0 ± 9.0 for biosimilars). Showing statistically significant differences among conditions. CONCLUSION: The emergence of biosimilar drugs has enhanced market competition and accelerated their adoption into hospitals' therapeutic regimens over original reference drugs. This has significantly improved access to biologic therapy for patients with IMIDs, evidenced by a notable 1.6-year reduction in access time for biosimilar drugs.
Sujet(s)
Produits pharmaceutiques biosimilaires , Humains , Produits pharmaceutiques biosimilaires/usage thérapeutique , Produits pharmaceutiques biosimilaires/économie , Études rétrospectives , Femelle , Mâle , Adulte d'âge moyen , Adulte , Biothérapie , Accessibilité des services de santé , Espagne , Maladies du système immunitaire/traitement médicamenteux , Sujet âgé , Infliximab/usage thérapeutique , Infliximab/économieRÉSUMÉ
Dupilumab and tralokinumab are currently the only FDA-approved biologic therapies for the treatment of moderate-to-severe atopic dermatitis. Tralokinumab is approved for patients greater than 18 years old, and dupilumab is approved for patients as young as 6 months old. Both medications are effective in clinical trials at improving atopic dermatitis. With a good safety profile and low-risk adverse events, dupilumab and tralokinumab are generally excellent treatment options for patients with severe or refractory atopic dermatitis.
Sujet(s)
Anticorps monoclonaux humanisés , Anticorps monoclonaux , Eczéma atopique , Eczéma atopique/traitement médicamenteux , Eczéma atopique/immunologie , Humains , Anticorps monoclonaux humanisés/usage thérapeutique , Anticorps monoclonaux humanisés/effets indésirables , Anticorps monoclonaux/usage thérapeutique , Biothérapie/méthodes , Résultat thérapeutiqueRÉSUMÉ
AIM: To assess effectiveness and safety of biological therapy in patients with severe asthma during 5 yr follow-up. MATERIALS AND METHODS: We recruited 129 adult outpatients (29% males) aged 18-81 yrs with severe asthma were followed up during 5 yrs and were examined for every 3-6 months. Eighty five patients were treated by conventional therapy (ICS/LABA ± tiotropium, montelukast, OCS) only and 44 pts additionally received biologicals (оmalizumab - 9 pts, мepolizumab - 8 pts, benralizumab - 11 pts, dupilumab - 16 pts). Pulmonary function tests were measured by dry spirometer (2120, Vitalograph Ltd., UK). Eosinophil count in blood was assessed by automatic haemoanalyser. Fraction of exhaled nitric oxide was measured by a chemiluminescence analyzer (LR4100; Logan Research, UK). Asthma control and quality of life were assessed by using Russian versions of ACQ-5 and SGRQ. RESULTS: The use of biologicals led to a more significant reduction of exacerbations and OCS use, improvement of lung function, asthma control and quality of life, decrease of eosinophil and fraction of exhaled nitric oxide than conventional therapy of severe asthma (p<0.05). Systemic side effects were not registered, frequency of local adverse reactions (edema, hyperemia and itching at injection site) was 14%. CONCLUSION: Long-term use of biologicals added to conventional therapy in patients with severe asthma is characterized by high effectiveness and favorable safety profile.
Sujet(s)
Asthme , Humains , Asthme/traitement médicamenteux , Asthme/physiopathologie , Mâle , Femelle , Adulte d'âge moyen , Adulte , Anticorps monoclonaux humanisés/administration et posologie , Anticorps monoclonaux humanisés/effets indésirables , Anticorps monoclonaux humanisés/usage thérapeutique , Antiasthmatiques/administration et posologie , Antiasthmatiques/effets indésirables , Antiasthmatiques/usage thérapeutique , Indice de gravité de la maladie , Qualité de vie , Tests de la fonction respiratoire/méthodes , Résultat thérapeutique , Sujet âgé , Biothérapie/méthodes , Biothérapie/effets indésirables , Jeune adulte , AdolescentRÉSUMÉ
Pediatric psoriasis is a chronic inflammatory skin condition. Current treatment modalities include topical medications, phototherapy, and systemic drugs, including biological agents. In cases of moderate-to-severe psoriasis recalcitrant to other therapies, biological therapies are often an attractive option given their dosing schedules, safety profiles, and need for less frequent laboratory monitoring, when compared with traditional systemic therapies. This article reviews biological treatment options approved for pediatric psoriasis and identifies others actively under investigation.
Sujet(s)
Adalimumab , Produits biologiques , Produits dermatologiques , Psoriasis , Ustékinumab , Humains , Psoriasis/traitement médicamenteux , Psoriasis/thérapie , Enfant , Adalimumab/usage thérapeutique , Produits biologiques/usage thérapeutique , Ustékinumab/usage thérapeutique , Produits dermatologiques/usage thérapeutique , Biothérapie , Infliximab/usage thérapeutique , Anticorps monoclonaux humanisés/usage thérapeutique , Étanercept/usage thérapeutique , Anticorps monoclonaux/usage thérapeutique , Rituximab/usage thérapeutique , Antagoniste du récepteur à l'interleukine-1/usage thérapeutique , Alefacept , Certolizumab pégol/usage thérapeutiqueRÉSUMÉ
INTRODUCTION: Effective treatment of severe asthma requires patient adherence to inhaled and biological medications. Previous work has shown that patient support programmes (PSP) can improve adherence in patients with chronic diseases, but the impact of PSPs in patients with severe asthma treated with biologics has not been thoroughly investigated. METHODS: We conducted a systematic literature review to understand the impact of PSPs on treatment adherence, asthma control and health-related quality of life (HRQoL) in patients with severe asthma. Embase, MEDLINE and EconLit databases were searched for studies published from 2003 (the year of the first biological approval for severe asthma) to June 2023 that described PSP participation among patients with severe asthma on biological treatment. Direct pooling of outcomes was not possible due to the heterogeneity across studies, so an indirect treatment comparison (ITC) was performed to determine the effect of PSP participation on treatment discontinuation. The ITC used patient-level data from patients treated with benralizumab either enrolled in a PSP (VOICE study, Connect 360 PSP) or not enrolled in a PSP (Benralizumab Patient Access Programme study) in the UK. FINDINGS: 25 records of 21 studies were selected. Six studies investigated the impact of PSPs on treatment adherence, asthma control or HRQoL. All six studies reported positive outcomes for patients enrolled in PSPs; the benefits of each PSP were closely linked to the services provided. The ITC showed that patients in the Connect 360 PSP group were less likely to discontinue treatment compared with the non-PSP group (OR 0.26, 95% CI 0.11 to 0.57, p<0.001). CONCLUSIONS: PSPs contribute to positive clinical outcomes in patients with severe asthma on biological treatment. Future analyses will benefit from thorough descriptions of PSP services, and study designs that allow direct comparisons of patient outcomes with and without a PSP.